Blood-based biomarkers hold tremendous promise for the early diagnosis, treatment, and tracking of neurodegenerative disorders, such as Alzheimer’s disease (AD). Researchers are increasingly turning their attention to Tau, a microtubule-associated protein biomarker with exceptional potential for early blood-based strategies that may improve neurodegenerative disease course.
Download this whitepaper to learn about the evolving role of Tau in neurodegenerative disease research and its multifaceted clinical applications.
